Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Molecular Insight Pharmaceuticals, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Molecular Insight Pharmaceuticals, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Molecular Insight Pharmaceuticals, Inc. since 2005.
The reporting company's ticker symbol is MIPI. The reporting company's CIK number is 1340752.
The total value of stock buying since 2005 is $2,553,876.
The total value of stock sales since 2005 is $187,908.
The total value of stock option exercises since 2005 is $692,999.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2011-01-28||Barlow David S (10% Owner)||Sale||59,000||.16||9,381|
|2011-01-27||Barlow David S (10% Owner)||Sale||38,000||.18||6,650|
|2010-12-17||Barlow David S (10% Owner)||Sale||155,000||.20||31,000|
|2010-12-16||Barlow David S (10% Owner)||Sale||45,000||.22||9,900|
|2010-01-14||Barlow David S (10% Owner)||Sale||5,800||1.99||11,536|
|2010-01-12||Barlow David S (10% Owner)||Sale||4,000||2.08||8,308|
|2009-12-24||Barlow David S (Director)||Sale||2,000||2.34||4,680|
|2009-12-23||Barlow David S (Director)||Sale||13,500||2.36||31,914|
|2009-12-21||Barlow David S (Director)||Sale||6,300||2.33||14,704|
|2009-12-18||Barlow David S (Director)||Sale||5,500||2.26||12,402|
|2009-05-29||Gottlieb Scott (Director)||Buy||4,000||3.83||15,320|
|2009-05-28||Lafrance Norman D. (Sr. VP Clinical Dev and CMO)||Sale||6,093||3.76||22,909|
|2009-05-22||Wallroth Donald E. (Chief Financial Officer)||Sale||6,500||3.77||24,524|
|2008-12-29||Barlow David S (Director)||Option Ex||81,249||3.60||292,496|
|2008-03-31||Hamermesh Joshua (VP Comm & Bus Development)||Option Ex||4,166||3.00||12,498|
|2008-03-24||Hamermesh Joshua (VP Comm & Bus Development)||Option Ex||8,334||3.00||25,002|
|2007-11-30||Lafrance Norman D. (Sr. VP Clinical Dev and CMO)||Buy||2,000||8.76||17,530|
|2007-11-30||Babich John W (President/Chief Scientific Officer)||Buy||2,500||8.34||20,862|
|2007-11-30||Barlow David S (Chief Executive Officer)||Buy||5,000||8.47||42,355|
|2007-11-29||Lafrance Norman D. (Sr. VP Clinical Dev and CMO)||Buy||2,000||8.00||16,000|
|2007-11-28||Frank Daniel (Director)||Option Ex||4,167||4.80||20,001|
|2007-11-27||Kronauge James F (VP Process Development)||Buy||7||6.50||45|
|2007-11-26||Kronauge James F (VP Process Development)||Buy||2,399||6.50||15,593|
|2007-11-20||Babich John W (President/Chief Scientific Officer)||Buy||10,000||6.90||69,050|
|2007-11-20||Barlow David S (Chief Executive Officer)||Buy||15,000||6.77||101,565|
|2007-11-08||Barlow David S (Chief Executive Officer)||Option Ex||75,001||3.60||270,003|
|2007-06-19||Hamermesh Joshua (VP Comm & Bus Development)||Option Ex||8,333||3.00||24,999|
|2007-03-30||Feinberg Stephen (10% Owner)||Buy||12,642||12.50||158,025|
|2007-03-29||Feinberg Stephen (10% Owner)||Buy||7,409||12.50||92,605|
|2007-03-28||Feinberg Stephen (10% Owner)||Buy||5,199||12.45||64,743|
|2007-02-28||Babich John W (President/Chief Scientific Officer)||Option Ex||80,000||.60||48,000|
|2007-02-28||Feinberg Stephen (10% Owner)||Buy||200||12.59||2,518|
|2007-02-23||Feinberg Stephen (10% Owner)||Buy||1,754||12.50||21,925|
|2007-02-20||Feinberg Stephen (10% Owner)||Buy||12,396||12.47||154,540|
|2007-02-16||Feinberg Stephen (10% Owner)||Buy||10,400||12.50||130,000|
|2007-02-02||Feinberg Stephen (10% Owner)||Buy||100,000||13.88||1,387,600|
|2007-02-01||Lamon Kim D (Director)||Buy||3,000||14.00||42,000|
|2007-02-01||Sterling Lionel N (Director)||Buy||14,400||14.00||201,600|
Insider trading activities including stock purchases, stock sales, and option exercises of MIPI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Molecular Insight Pharmaceuticals, Inc. (symbol MIPI, CIK number 1340752) see the Securities and Exchange Commission (SEC) website.